Exact Sciencesの空売り状況は、投資家がExact Sciencesの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Exact Sciences (NASDAQ:EXAS) 株価情報, 空売り情報

Exact Sciences

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Exact Sciences Corporation - Common Stock

Exact Sciences Corp

Exasol AG

U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Tuesday.
Shares of The J. M. Smucker Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) rose sharply during Tuesday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS guidance with its <a href="https://www.benzinga.com/news/earnings/24/11/42189572/j-m-smucker-q2-earnings-beat-17-sales-surge-fy25-eps-outlook-boost-more">midpoint above estimates.</a>
Smucker shares surged 6.2% to $120.60 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares jumped 59% to $7.55 after the company reported better-than-expected third-quarter sales results.</li>
<li>Embecta Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) gained 30.2% to $18.76 after the company reported better-than-expected fourth-quarter financial results and issued FY25 adjusted EPS guidance above estimates.</li>
<li>LexinFintech Holdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) surged 22.8% to $4.1750 after the company announced its board approved an amendment for a dividend policy to increase the payout ratio. Also, the company reported third-quarter financial results.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) gained 20.3% to $64.32 as the company reported better-than-expected third-quarter financial results and issued fourth-quarter guidance with its midpoint above estimates.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARWR#NASDAQ">ARWR</a>) gained 18.1% to $22.17 after the company entered into a global licensing and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical siRNA programs.</li>
<li>Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) shares rose 15% to $25.65.</li>
<li>SmartRent, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) gained 13.8% to $1.8450.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) gained 12.6% to $2.1850.</li>
<li>POET Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) surged 12.2% to $4.77. POET Technologies recently announced plans to expand its capacity.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares gained 9.1% to $125.10 after the company announced a global licensing and collaboration agreement with Arrowhead Pharmaceuticals for multiple clinical and preclinical siRNA programs.</li>
<li>NRG Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>) gained 8% to $99.21 after Jefferies upgraded the stock from Hold to Buy and raised its price target from $93 to $113.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) surged 7.8% to $59.45. The company announced it will present 10 abstracts at SABCS.</li>
<li>Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) surged 7.4% to $192.62 after the company reported better-than-expected fourth-quarter EPS and sales.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 7.3% to $25.82.</li>
<li>Hanesbrands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) gained 5.8% to $8.94. UBS analyst Jay Sole upgraded Hanesbrands from Neutral to Buy and raised the price target from $9 to $11.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/24/11/42190113/starbucks-to-rally-around-13-here-are-10-top-analyst-forecasts-for-tuesday">Starbucks To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

News

Intraday Update

Markets

Movers

Trading Ideas

ARWR

EMBC

EXAS

HSAI

NGNE

POET

RKLB

SGMO

SMRT

SMTC

SRPT

J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

WIIM

Exact Sciences shares are trading higher. The company announced it will present 10 abstracts at SABCS.

U.S. stocks could open on a sluggish note on Tuesday after ending in green on Monday as President-elect Donald Trump threatened to hit two of U.S.&#8217;s largest trading partners &#8211; Canada and Mexico &#8211; with tariffs.
The Dollar Index strengthened and was hovering around the 107 level. Expectations of a further 25 basis point rate cut in December have fallen to just 59% now, down from 75% a month ago, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group's FedWatch tool.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.08%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.09%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.07%</td>
</tr>
<tr>
<td>R2K</td>
<td>-0.26%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.06% to $597.87 and the Invesco QQQ ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NYSE">QQQ</a>) rose 0.04% to $506.80, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
The Dow Jones closed higher by around 440 points to 44,736.57 on Monday. The S&amp;P 500 rose 0.30% to 5,987.37, while the Nasdaq Composite rose 0.27% to close at 19,054.84 during Monday&#8217;s session.
On the economic data front, the Chicago Fed National Activity Index fell to -0.40 in October compared to -0.27 in the previous month and versus market estimates of -0.20.
The Dallas Fed&#8217;s Texas manufacturing activity index rose to -2.7 in November compared to a reading of -3 in the previous month and versus market estimates of -2.4.
Most sectors on the S&amp;P 500 closed on a positive note, with real estate, materials, and consumer discretionary stocks recording the biggest gains on Monday.
However, energy and information technology stocks bucked the overall market trend, closing the session lower.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.27%</td>
<td>19,054.84</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.30%</td>
<td>5,987.37</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.99%</td>
<td>44,736.57</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.47%</td>
<td>2,442.03</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
&#8220;Equity markets continue to display remarkable strength. The S&amp;P 500 and other major indices are flirting with or surpassing all-time highs. The breadth of the rally is particularly noteworthy, with a growing number of stocks hitting 52-week highs,&#8221; said Jeremy Siegel, a senior economist <a href="https://resources.wisdomtree.com/weekly-siegel-commentary/">at</a> WisdomTree.
&#8220;This breadth is a key signal of market health, as it indicates a robust and inclusive rally rather than one concentrated in a few mega-cap names,&#8221; he added.
Analysts at BlackRock <a href="https://www.blackrock.com/us/individual/insights/blackrock-investment-institute/weekly-commentary">said</a> that they are positive about the AI theme in the technology sector. &#8220;Valuations for AI beneficiaries are supported as tech companies keep beating high earnings expectations. We think upbeat sentiment can broaden out,&#8221; their note said.
BlackRock also added that they see the AI buildout and adoption creating opportunities across sectors. &#8220;We get selective, moving toward beneficiaries outside the tech sector. Broad-based earnings growth and a quality tilt make us overweight U.S. stocks overall.&#8221;
Predicting how December could look like for the stock markets, Ryan Detrick, chief market strategist at Carson Group, highlighted how markets have performed better than average in December in every election year since 1950.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">No month is more likely to be higher than December in an election year (83.3%). <a href="https://t.co/WrOI59tUiR">pic.twitter.com/WrOI59tUiR</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1861092399449284637?ref_src=twsrc%5Etfw">November 25, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Upcoming Economic Data:
This week&#8217;s economic calendar is not as packed as last week&#8217;s due to Thanksgiving. Here are the key events lined up for Tuesday:
<ul>
<li>The S&amp;P Case-Shiller home price index for 20 cities will be released at 9 a.m. ET.</li>
<li>Data on consumer confidence and new home sales will be released at 10 a.m. ET.</li>
<li>The minutes of the Fed's November FOMC meeting will be released at 2 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Woodward Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) is up by almost 11% in premarket trading after Pathstone Holdings LLC boosted its position by 28.6% during the 3rd quarter, as per SEC filing. The company also reported a record revenue of $3 billion in the September quarter, aided by the performance in both aerospace and industrial segments.</li>
<li>Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) rose 6% in premarket as it reacted to reports that Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) reached a "conditional" settlement concerning a 2020 lawsuit. The Elon Musk-led company had accused Rivian of poaching Tesla employees to get ahold of its EV trade secrets.</li>
<li>Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) was trading above 5.5% in premarket after the company advanced breast cancer care with the Oncotype DX test and genomic profiling research at the San Antonio Breast Cancer Symposium 2024.</li>
<li>Semtech Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) was up over 19% in premarket hours after the chipmaker reported a strong set of earnings. The company posted revenue of $236.8 million for the quarter with quarterly earnings of $0.26 per share as compared to $0.02 per share a year ago.</li>
<li>Blue Bird Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) was down over 10% in premarket after its fourth-quarter earnings missed analyst estimates. The quarterly earnings of $0.77 per share missed the Zacks Consensus Estimate of $0.78 per share. This compares to the EPS of $0.66 in Q4 of the previous fiscal.</li>
<li>Investors are awaiting earnings results from Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>), HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>), and Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures rose in the early New York session, advancing 0.93% to hover around $69.57.
The 10-year Treasury note yield eased to 4.293%.
Major Asian markets ended lower on Tuesday, except for Hong Kong&#8217;s Hang Seng Index. European markets were also down in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42180029/ark-invest-shakes-up-portfolio-with-big-tesla-and-amazon-trades">Cathie Wood-Led Ark Invest&#8217;s Latest Portfolio Maneuver: Dumps Tesla And Palantir Shares, Buys Amazon And AMD Stock</a></li>
</ul>
Photo courtesy: Wikimedia

Earnings

Equities

Economics

Federal Reserve

Pre-Market Outlook

BLBD

DELL

RIVN

TSLA

US Stocks May Have A Slow Start As Trump's Tariff Threat Begins To Thwart Relief Rally: Analysts Remain Optimistic About AI-Linked Sectors Stocks

The company said new data supports the value of the Oncotype DX Breast Recurrence Score test in guiding treatment decisions, improving outcomes, and managing costs for breast cancer patients globally.

Exact Sciences To Present 10 Abstracts Demonstrating Breadth Of Its Precision Oncology Portfolio At SABCS

New evidence shows multi-biomarker class approach improved cancer detection, including in earlier stages when treatment may be more effective
Modeling data estimate adding MCED testing to standard-of-care screening could reduce cancer mortality by 17%
New analysis from DETECT-A study supports MCED testing as a complement to current guideline-recommended screening
Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection (MCED) test. The results of a study evaluating a new multi-biomarker class approach showed improved sensitivity for early-stage and overall cancer detection. In addition, new modeling data estimate that adding MCED testing to recommended screening may reduce the incidence of stage IV cancer and, subsequently, cancer mortality over 10 years. Another new analysis from the DETECT-A study suggests that adding MCED testing complements guideline-recommended lung cancer screening without affecting adherence to current standard of care. These findings will be presented at the American Association for Cancer Research (AACR) Special Conference in Cancer Research: Liquid Biopsy from November 13-16, 2024, in San Diego, Calif.

Biotech

General

Exact Sciences Unveils Data Showing Multi-Cancer Early Detection At AACR Special Conference On Liquid Biopsy; New Evidence Shows Multi-Biomarker Class Approach Improved Cancer Detection, Including In Earlier Stages When Treatment May Be More Effective; Modeling Data Estimate Adding MCED Testing To Standard-Of-Care Screening Could Reduce Cancer Mortality By 17%

Insider Trades

Exact Sciences CEO Kevin Conroy Buys 19,500 Shares At $51.35 Each, Investing $1M; Now Holds 1.07M Direct Shares, With Total Holdings Reaching 1.41M Shares Plus 683K Options And Restricted Stock Units

Piper Sandler analyst David Westenberg maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight and lowers the price target from $85 to $75.

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on Exact Sciences, Lowers Price Target to $75

Citigroup analyst Patrick Donnelly maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $80 to $75.

Citigroup Maintains Buy on Exact Sciences, Lowers Price Target to $75

Jefferies analyst Brandon Couillard maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and raises the price target from $84 to $85.

Jefferies Maintains Buy on Exact Sciences, Raises Price Target to $85

BTIG analyst Mark Massaro maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $82 to $65.

BTIG Maintains Buy on Exact Sciences, Lowers Price Target to $65

Stifel analyst Daniel Arias maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $82 to $67.

Stifel Maintains Buy on Exact Sciences, Lowers Price Target to $67

Canaccord Genuity analyst Kyle Mikson maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $95 to $75.

Canaccord Genuity Maintains Buy on Exact Sciences, Lowers Price Target to $75

TD Cowen analyst Dan Brennan maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $90 to $82.

TD Cowen Maintains Buy on Exact Sciences, Lowers Price Target to $82

Goldman Sachs analyst Matthew Sykes maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $75 to $65.

Goldman Sachs Maintains Buy on Exact Sciences, Lowers Price Target to $65

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock moved upwards by 77.9% to $7.49 during Wednesday's regular session. The company's market cap stands at $38.9 million. </li>
<li>Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares moved upwards by 29.22% to $7.03. The company's market cap stands at $924.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) stock increased by 23.78% to $7.13. The market value of their outstanding shares is at $443.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares moved upwards by 21.63% to $2.98. The company's market cap stands at $104.0 million. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock moved upwards by 21.26% to $0.34. The market value of their outstanding shares is at $10.5 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock increased by 16.24% to $5.94. The company's market cap stands at $108.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Tango Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNGX#NASDAQ">TNGX</a>) stock declined by 39.6% to $3.13 during Wednesday's regular session. The company's market cap stands at $335.3 million. As per the press release, Q3 earnings came out today. </li>
<li>PACS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares decreased by 39.39% to $17.91. The market value of their outstanding shares is at $2.7 billion. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock declined by 31.98% to $0.09. The market value of their outstanding shares is at $1.5 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares declined by 31.5% to $1.74. The market value of their outstanding shares is at $1.8 million. </li>
<li>Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) stock decreased by 27.36% to $51.95. The company's market cap stands at $9.5 billion. The company's, Q3 earnings came out yesterday. </li>
<li>Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) stock decreased by 22.71% to $88.86. The market value of their outstanding shares is at $6.1 billion. As per the news, the Q3 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

CTKB

LNTH

OPRX

PACS

RAPT

SONN

TMCI

TNGX

ZVSA

12 Health Care Stocks Moving In Wednesday's Intraday Session

Evercore ISI Group analyst Vijay Kumar maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Outperform and lowers the price target from $80 to $60.

Evercore ISI Group Maintains Outperform on Exact Sciences, Lowers Price Target to $60

On Tuesday, Exact Sciences Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus loss estimate of $0.20.</a>
The reported quarterly sales of $708.66 million missed the consensus <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41757648/exact-sciences-announces-third-quarter-2024-results" rel="noreferrer noopener">estimate of $717.66 million</a>.
Screening revenue was $545 million, an increase of 15%, and Precision Oncology&#8217;s revenue was $164 million, an increase of 5% on a reported and core revenue basis.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/10/41185292/fda-clears-exact-sciences-next-generation-colorectal-cancer-diagnostic-test" rel="noreferrer noopener">FDA Clears Exact Sciences&#8217; Next-Generation Colorectal Cancer Diagnostic Test</a>.
&#8220;While we have made progress, our execution during the third quarter and updated outlook for the full year don&#8217;t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong,&#8221; said Kevin Conroy, chairman and CEO.
Guidance: Exact Sciences cuts its 2024 revenue guidance from $2.81 billion-$2.85 billion to $2.73 billion-$2.75 billion compared to the consensus of $2.832 billion.
The guidance includes a Screening sales forecast of $2.08 billion—$2.095 billion, compared to previous guidance of $2.155 billion—$2.175 billion.
Precision Oncology sales are expected to be $650 million- $655 million, down from prior guidance of $655 million &#8211; $675 million.
The company expects 2024 Adjusted EBITDA of $310 million—$320 million, down from previous guidance of $335 million—$355 million.
William Blair notes that management attributed the lower-than-expected guidance primarily to challenges affecting the screening segment.
While these explanations are logical, they raise questions about why certain factors weren&#8217;t identified or addressed sooner. Management, however, took full responsibility and conveyed a sincere commitment to improving performance, the analyst writes.
Despite these hurdles, the analyst remains optimistic about revenue growth in 2025, highlighting several factors within the company&#8217;s control.
William Blair emphasizes that investors will likely want to see clear signs of improved execution and revenue growth resuming in 2025.
With shares trading down, the analyst writes that valuation is at a compelling long-term entry point.
Price Action: At last check on Wednesday, EXAS stock was down 28.50% at $51.16.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41753865/apollos-fee-related-earnings-growth-sets-it-apart-in-alternative-assets-says-goldma" target="_blank" rel="noreferrer noopener">Apollo&#8217;s Fee-Related Earnings Growth Sets It Apart in Alternative Assets, Says Goldman Sachs With Bullish EPS Forecast</a></li>
</ul>

Analyst Color

Guidance

Health Care

Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point

Craig-Hallum analyst Alex Nowark maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $82 to $65.

Craig-Hallum Maintains Buy on Exact Sciences, Lowers Price Target to $65

Benchmark analyst Bruce Jackson maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $67 to $65.

Benchmark Maintains Buy on Exact Sciences, Lowers Price Target to $65

U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday.
Shares of Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) fell sharply in today's pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 revenue <a href="https://www.benzinga.com/general/biotech/24/11/41760212/exact-sciences-stock-plummets-after-worse-than-expected-q3-results-fy24-guidance-below-estimates">guidance below estimates</a>.
Exact Sciences reported quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million missed the consensus estimate of $717.66 million.
Exact Sciences shares dipped 27% to $52.20 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) fell 24.3% to $20.97 in pre-market trading after the company lowered its financial outlook. The company expects to report first-quarter revenue of $5.9 billion to $6 billion, down from its previous guidance range of $6 billion to $7 billion. The company anticipates adjusted earnings of 75 cents to 76 cents per share, versus its previous guidance of 67 cents to 83 cents per share.</li>
<li>Gevo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) fell 20.8% to $1.86 in today's pre-market trading.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) fell 20.1% to $5.64 in pre-market trading after gaining 8% on Tuesday.</li>
<li>PACS Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares fell 18.8% to $24.00 in pre-market trading after the company announced postponement of third-quarter results and disclosure on civil investigative demands from the federal government.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) fell 18.6% to $13.76 in pre-market trading after gaining 5% on Tuesday.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) declined 16.8% to $3.81 in pre-market trading following weak quarterly results.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) shares fell 16.8% to $15.25 in pre-market trading.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) shares fell 14.7% to $184.00 in pre-market trading.</li>
<li>The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) declined 9.9% to $13.97 in pre-market trading.</li>
<li>Honda Motor Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMC#NYSE">HMC</a>) shares fell 7.4% to $28.05 in pre-market trading as the company said profits fell around 20% in the first half of the fiscal year.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

FSLR

GEVO

NOVA

OSCR

SMCI

Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Exact Sciences Corporation (EXAS) Jefferies London Healthcare Conference (Transcript)

Jefferies analyst Tycho Peterson maintained a Buy rating on Exact Sciences (EXAS – Research Report) today and set a price target of $85.00. The com...

Exact Sciences (EXAS) Receives a Buy from Jefferies

Exact Sciences (EXAS) Corp. will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio ...

Exact Sciences to present 10 abstracts on Precision Oncology portfolio at SABCS

Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGS – Semtech (SMTC) up 14.6% ALSO HIGHER – Exa...

Closing Bell Movers: Semtech rises, Zoom falls after earnings

Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Brandon Couillard...

Exact Sciences' Revenue Boost: Impact of CMS Pricing Decision on Cologuard Plus

Piper Sandler analyst David Westenberg assigned a Buy rating to Exact Sciences (EXAS – Research Report) today and set a price target of $75.00. The...

Piper Sandler Releases a Buy Rating on Exact Sciences (EXAS)

Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Exact Sciences (EXAS – Research Report) today and set a price target of $67.00. The...

Exact Sciences (EXAS) Receives a Buy from Stifel Nicolaus

TD Cowen analyst Dan Brennan raised the firm's price target on Exact Sciences (EXAS) to $86 from $82 and keeps a Buy rating on the shares. The firm...

Exact Sciences price target raised to $86 from $82 at TD Cowen

BTIG raised the firm's price target on Exact Sciences (EXAS) to $75 from $65 and keeps a Buy rating on the shares. The firm notes shares of Exact S...

Exact Sciences price target raised to $75 from $65 at BTIG

BTIG analyst Mark Massaro reiterated a Buy rating on Exact Sciences (EXAS – Research Report) today and set a price target of $75.00. Mark Massaro h...

Comments

Exact Sciences

空売り

Exact Sciences (NASDAQ:EXAS) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル